Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TOP2A | P11388 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13007600 | 0.82 | ALDH1A1 (0.54) | LMNAALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL5848939 | 0.80 | ALDH1A1 (0.56) | LMNAALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL6498162 | 0.80 | ALDH1A1 (0.43) | LMNAALDH1A1SMN1; SMN2HPGDCA1 | |
| SCHEMBL5856769 | 0.76 | ALDH1A1 (0.57) | LMNAALDH1A1SMN1; SMN2CA1CA2 | |
| SCHEMBL6670720 | 0.75 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL6496575 | 0.74 | ALDH1A1 (0.41) | LMNAALDH1A1SMN1; SMN2TSHRHPGD | |
| SCHEMBL9756822 | 0.74 | LMNA (0.60) | LMNAALDH1A1SMN1; SMN2TSHRCA1 | |
| SCHEMBL25191613 | 0.72 | LMNA (0.53) | LMNAALDH1A1SMN1; SMN2TSHRHPGD | |
| SCHEMBL17234481 | 0.72 | ALDH1A1 (0.60) | LMNAALDH1A1HPGDCA1CA2 | |
| SCHEMBL6490227 | 0.71 | ALDH1A1 (0.65) | ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115741-B2 | 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds | ALEXION PHARMACEUTICALS, INC. | 2006-10-03 | — | — | US | disclosed |
| US-20030153556-A1 | Piperazine and homopiperazine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
| WO-2003022214-A2 | PIPERAZINE AND HOMOPIPERAZINE COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153556-A1 | Piperazine and homopiperazine compounds | HAMP, MPL, F2 | LMNA 4352/4885ALDH1A1 3346/4885SMN1; SMN2 4536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.